Exploring the Potential Role of Upper Abdominal Peritonectomy in Advanced Ovarian Cancer Cytoreductive Surgery Using Explainable Artificial Intelligence
- PMID: 38001646
- PMCID: PMC10670755
- DOI: 10.3390/cancers15225386
Exploring the Potential Role of Upper Abdominal Peritonectomy in Advanced Ovarian Cancer Cytoreductive Surgery Using Explainable Artificial Intelligence
Abstract
The Surgical Complexity Score (SCS) has been widely used to describe the surgical effort during advanced stage epithelial ovarian cancer (EOC) cytoreduction. Referring to a variety of multi-visceral resections, it best combines the numbers with the complexity of the sub-procedures. Nevertheless, not all potential surgical procedures are described by this score. Lately, the European Society for Gynaecological Oncology (ESGO) has established standard outcome quality indicators pertinent to achieving complete cytoreduction (CC0). There is a need to define what weight all these surgical sub-procedures comprising CC0 would be given. Prospectively collected data from 560 surgically cytoreduced advanced stage EOC patients were analysed at a UK tertiary referral centre.We adapted the structured ESGO ovarian cancer report template. We employed the eXtreme Gradient Boosting (XGBoost) algorithm to model a long list of surgical sub-procedures. We applied the Shapley Additive explanations (SHAP) framework to provide global (cohort) explainability. We used Cox regression for survival analysis and constructed Kaplan-Meier curves. The XGBoost model predicted CC0 with an acceptable accuracy (area under curve [AUC] = 0.70; 95% confidence interval [CI] = 0.63-0.76). Visual quantification of the feature importance for the prediction of CC0 identified upper abdominal peritonectomy (UAP) as the most important feature, followed by regional lymphadenectomies. The UAP best correlated with bladder peritonectomy and diaphragmatic stripping (Pearson's correlations > 0.5). Clear inflection points were shown by pelvic and para-aortic lymph node dissection and ileocecal resection/right hemicolectomy, which increased the probability for CC0. When UAP was solely added to a composite model comprising of engineered features, it substantially enhanced its predictive value (AUC = 0.80, CI = 0.75-0.84). The UAP was predictive of poorer progression-free survival (HR = 1.76, CI 1.14-2.70, P: 0.01) but not overall survival (HR = 1.06, CI 0.56-1.99, P: 0.86). The SCS did not have significant survival impact. Machine Learning allows for operational feature selection by weighting the relative importance of those surgical sub-procedures that appear to be more predictive of CC0. Our study identifies UAP as the most important procedural predictor of CC0 in surgically cytoreduced advanced-stage EOC women. The classification model presented here can potentially be trained with a larger number of samples to generate a robust digital surgical reference in high output tertiary centres. The upper abdominal quadrants should be thoroughly inspected to ensure that CC0 is achievable.
Keywords: complete cytoreduction; epithelial ovarian cancer; explainable artificial intelligence; machine learning; survival; upper abdominal peritonectomy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures








Similar articles
-
Development of a Novel Intra-Operative Score to Record Diseases' Anatomic Fingerprints (ANAFI Score) for the Prediction of Complete Cytoreduction in Advanced-Stage Ovarian Cancer by Using Machine Learning and Explainable Artificial Intelligence.Cancers (Basel). 2023 Feb 3;15(3):966. doi: 10.3390/cancers15030966. Cancers (Basel). 2023. PMID: 36765924 Free PMC article.
-
Explainable Artificial Intelligence for Prediction of Complete Surgical Cytoreduction in Advanced-Stage Epithelial Ovarian Cancer.J Pers Med. 2022 Apr 10;12(4):607. doi: 10.3390/jpm12040607. J Pers Med. 2022. PMID: 35455723 Free PMC article.
-
Factors Predicting Surgical Effort Using Explainable Artificial Intelligence in Advanced Stage Epithelial Ovarian Cancer.Cancers (Basel). 2022 Jul 15;14(14):3447. doi: 10.3390/cancers14143447. Cancers (Basel). 2022. PMID: 35884506 Free PMC article.
-
The Use of Artificial Intelligence for Complete Cytoreduction Prediction in Epithelial Ovarian Cancer: A Narrative Review.Cancer Control. 2023 Jan-Dec;30:10732748231159553. doi: 10.1177/10732748231159553. Cancer Control. 2023. PMID: 36847148 Free PMC article. Review.
-
Novel Surgical Strategies in the Treatment of Gynecological Malignancies.Curr Treat Options Oncol. 2018 Nov 9;19(12):73. doi: 10.1007/s11864-018-0582-5. Curr Treat Options Oncol. 2018. PMID: 30411170 Review.
Cited by
-
Assessment of Intraoperative Scoring Systems for Predicting Cytoreduction Outcome in Peritoneal Metastatic Disease: A Systematic Review and Meta-analysis.Ann Surg Oncol. 2024 Oct;31(10):7165-7183. doi: 10.1245/s10434-024-15629-7. Epub 2024 Jun 25. Ann Surg Oncol. 2024. PMID: 38918326
-
Artificial Intelligence in Gynecological Oncology from Diagnosis to Surgery.Cancers (Basel). 2025 Mar 21;17(7):1060. doi: 10.3390/cancers17071060. Cancers (Basel). 2025. PMID: 40227612 Free PMC article. Review.
-
Mapping the Advanced-Stage Epithelial Ovarian Cancer Landscape Goes Beyond Words: Two Large Language Models, Eight Tasks, One Journey.J Clin Med. 2025 Mar 25;14(7):2223. doi: 10.3390/jcm14072223. J Clin Med. 2025. PMID: 40217674 Free PMC article.
References
-
- Du Bois A., Quinn M., Thigpen T., Vermorken J., Avall-Lundqvist E., Bookman M., Bowtell D., Brady M., Casado A., Cervantes A., et al. 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann. Oncol. 2005;16:viii7–viii12. doi: 10.1093/annonc/mdi961. - DOI - PubMed
-
- Monk B.J., Coleman R.L., Fujiwara K., Wilson M.K., Oza A.M., Oaknin A., O’Malley D.M., Lorusso D., Westin S.N., Safra T., et al. ATHENA (GOG-3020/ENGOT-ov45): A randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int. J. Gynecol. Cancer. 2021;31:1589–1594. - PMC - PubMed
LinkOut - more resources
Full Text Sources